Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

NRAS G13D

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

EGFR exon 19 deletion + NRAS Q61K (3)

PD-L1 expression + NRAS Q61R + BRAF D594N (2)

CDKN2A Negative + NRAS Mutation (1)

Chr t(11;14) + NRAS mutation (1)

KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)

MLL-AFF1 fusion + NRAS mutation (1)

NRAS mutation + BRAF wild-type (1)

NRAS wild-type + NOTCH4 mutation (1)

EGFR exon 19 deletion + NRAS Q61K (3)

PD-L1 expression + NRAS Q61R + BRAF D594N (2)

CDKN2A Negative + NRAS Mutation (1)

Chr t(11;14) + NRAS mutation (1)

KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)

MLL-AFF1 fusion + NRAS mutation (1)

NRAS mutation + BRAF wild-type (1)

NRAS wild-type + NOTCH4 mutation (1)

›

NRAS G13D	Multiple Myeloma	NRAS G13D	Multiple Myeloma	bortezomib Sensitive: D – Preclinical bortezomib Sensitive : D	bortezomib Sensitive: D – Preclinical bortezomib Sensitive : D
NRAS G13D	Melanoma	NRAS G13D	Melanoma	atezolizumab + RG6185 Sensitive: D – Preclinical atezolizumab + RG6185 Sensitive : D	atezolizumab + RG6185 Sensitive: D – Preclinical atezolizumab + RG6185 Sensitive : D
NRAS G13D	Mantle Cell Lymphoma	NRAS G13D	Mantle Cell Lymphoma	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D